Bone Metastases, Hormone Refractory Prostate Cancer
Conditions
Keywords
prostate cancer, cisplatin, strontium-89, phase II
Brief summary
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Detailed description
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.
Interventions
DRUGstrontium-89
DRUGcisplatin
Sponsors
The Prostate Cancer Research Foundation of Canada
Amersham Health
Alberta Health services
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* adenocarcinoma of the prostate * life expectancy \> 3 months, * symptomatic from bone metastases * radiologic evidence of metastatic bone disease * stable level of pain control * \>18 years * ability to complete assessments * prior treatment (chemo) \> 4 weeks previous * discontinued anti-androgens for \> 4 weeks
Exclusion criteria
* prior strontium therapy * previous hemibody RT within 6 weeks * previous cytotoxic chemotherapy within 4 weeks * use of bisphosphonate medications within 4 weeks * change in steroid dose within 4 weeks * active uncontrolled infection * impending or present spinal cord compression * significant neurological disorder * impending pathological fracture * severe urinary incontinence
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Palliative pain response | — |
| analgesic response | — |
Countries
Canada
Outcome results
None listed